About: Pharmacogenomics of metabolic effects of rosiglitazone     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • We compared the effect of rosiglitazone (RSG) in adult male rats of two genetically defined models of metabolic syndrome, the PD/Cub and BN.SHR4 rat strains, in contrast to their insulin-sensitive, normolipidemic counterpart, the Brown Norway strain. All rats were fed high-fat diet for the period of four weeks, the experimental groups received RSG (0.4mg/100g body weight) during the last two weeks of HFD-feeding. The mass and the sensitivity of visceral adipose tissue to insulin-stimulated lipogenesis increased with RSG treatment only in PD, corresponding with significant increase in expression of prostaglandin D2 synthase. The glucose tolerance was enhanced in all strains. The genes with genotype-specific expression change included aquaporin 9, ADAM metallopeptidase domain 7, catechol-O-methyl transferase and carnitine palmitoyltransferase 1B. In conclusion, RSG effects on lipid deposition and insulin sensitivity of peripheral tissues were largely dependent on the diet-modulated, pharmacogenomic i
  • We compared the effect of rosiglitazone (RSG) in adult male rats of two genetically defined models of metabolic syndrome, the PD/Cub and BN.SHR4 rat strains, in contrast to their insulin-sensitive, normolipidemic counterpart, the Brown Norway strain. All rats were fed high-fat diet for the period of four weeks, the experimental groups received RSG (0.4mg/100g body weight) during the last two weeks of HFD-feeding. The mass and the sensitivity of visceral adipose tissue to insulin-stimulated lipogenesis increased with RSG treatment only in PD, corresponding with significant increase in expression of prostaglandin D2 synthase. The glucose tolerance was enhanced in all strains. The genes with genotype-specific expression change included aquaporin 9, ADAM metallopeptidase domain 7, catechol-O-methyl transferase and carnitine palmitoyltransferase 1B. In conclusion, RSG effects on lipid deposition and insulin sensitivity of peripheral tissues were largely dependent on the diet-modulated, pharmacogenomic i (en)
  • Byl porovnán účinek rosiglitazonu (RSG) u dospělých samců u dvou geneticky definovaných modelů metabolického syndrome, PD/Cub a BN.SHR4 a kontrolního insulin senzitivního kmene Brown Norway. Potkani byli krmeni vysokotukovou dietou po dobu 4 týdnů, experimentální skupina dostávala RSG v dávce 0,4mg/100g tělesné hmotnosti. RGG zvyšoval senzitivitu tukové tkáně k účinku inzulinu u PD potkanů, která byla spojena se vyšší expresí prostaglandin D2 syntázy. RSG pozitivně ovlivnil glukózovou tolerance u všech srovnávaných kmenů. RSG zvýšil expresi genů pro aquaporin 9, ADAM metallopeptidázu, catechol-O-methyl transferázu and carnitine palmitoyltransferázu 1B.Vliv RSG byl závislý na farmakogenomické interakci. (cs)
Title
  • Pharmacogenomics of metabolic effects of rosiglitazone
  • Pharmacogenomics of metabolic effects of rosiglitazone (en)
  • Faramkogenomika metabolických účinků rosiglitazonu (cs)
skos:prefLabel
  • Pharmacogenomics of metabolic effects of rosiglitazone
  • Pharmacogenomics of metabolic effects of rosiglitazone (en)
  • Faramkogenomika metabolických účinků rosiglitazonu (cs)
skos:notation
  • RIV/00023001:_____/08:00001764!RIV09-MZ0-00023001
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(NR8495), Z(MSM0021620807)
http://linked.open...iv/cisloPeriodika
  • 2
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 386454
http://linked.open...ai/riv/idVysledku
  • RIV/00023001:_____/08:00001764
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Rosiglitazone; metabolic syndrome; lipogenesis; pharmacogenomic interaction (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [A98EF3123DC1]
http://linked.open...i/riv/nazevZdroje
  • Pharmacogenomics
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 9
http://linked.open...iv/tvurceVysledku
  • Kazdová, Ludmila
  • Oliyarnyk, Olena
  • Corbeil, G.
  • Hamet, P.
  • Tremblay, J.
  • Šedová, L.
  • Šeda, Ondřej
  • Křen, V.
  • Křenová, D.
http://linked.open...ain/vavai/riv/wos
  • 000257993100002
http://linked.open...n/vavai/riv/zamer
issn
  • 1462-2416
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 24 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software